Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aeterna Zentaris Cancer Drug Gets Orphan Drug Designation | Contract Pharma

What are you searching for?

Sign in

Aeterna Zentaris Cancer Drug Gets Orphan Drug Designation

Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer. AEZS-108 is currently in a Phase II trial in advanced ovarian and endometrial cancer.

Orphan drug designation is granted to new drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides a seven-year period of marketing exclusivity if approved, or if it demonstrates superior safety and efficacy versus another drug for the same indication.

Juergen Engel, Ph.D., president and chief executive officer of Aeterna Zentaris said, “We are very pleased with AEZS-108 gaining orphan-drug designation for ovarian cancer from the FDA as it would provide it with extra market exclusivity protection. We look forward to reporting the final results from our ongoing European Phase II study in ovarian and endometrial cancer, later this year.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters